ストックスクリーナーアプリを入手
3.22
1.26%
0.04
前日終値:
$3.18
開ける：
$3.26
24時間の取引高:
28,570
Relative Volume:
0.52
時価総額：
$26.48M
収益：
$442.00K
当期純損益:
$-30.46M
株価収益率:
-0.722
EPS:
-4.46
ネットキャッシュフロー:
$-27.47M
1週間 パフォーマンス:
-22.22%
1か月 パフォーマンス:
-27.15%
6か月 パフォーマンス:
-33.20%
1年 パフォーマンス:
-62.15%
1日の値動き範囲:
$3.10
$3.3407
1週間の範囲:
$3.09
$4.20
52週間の値動き範囲:
$3.09
$9.20
Clene Inc Stock (CLNN) Company Profile
名前
Clene Inc
電話
801-676-9695
住所
6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
CLNN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CLNN
Clene Inc
|
3.22 | 26.48M | 442.00K | -30.46M | -27.47M | -4.46 |
|
KHC
Kraft Heinz Co
|
30.24 | 36.72B | 25.85B | 2.74B | 3.02B | 2.26 |
|
GIS
General Mills Inc
|
59.11 | 32.67B | 19.64B | 2.56B | 2.48B | 4.55 |
|
K
Kellanova
|
82.47 | 28.11B | 12.75B | 1.34B | 1.13B | 3.87 |
|
MKC
Mccormick Co Inc
|
81.46 | 21.89B | 6.68B | 792.60M | 774.40M | 2.94 |
|
HRL
Hormel Foods Corp
|
30.36 | 16.67B | 11.92B | 805.04M | 1.01B | 1.46 |
Clene Inc Stock (CLNN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-10-04 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-07-18 | 開始されました | H.C. Wainwright | Buy |
| 2022-05-02 | 開始されました | Canaccord Genuity | Buy |
| 2021-09-28 | 開始されました | Oppenheimer | Outperform |
Clene Inc (CLNN) 最新ニュース
Roth Capital Has Negative Estimate for Clene Q1 Earnings - Defense World
Clene Inc. settles debt with equity issuance - Investing.com
Clene Inc.'S (NASDAQ: CLNN) Q1 Virtual Investor Summit Presentation Available For On-Demand Viewing - MENAFN.COM
Roth Capital Has Optimistic Outlook of Clene FY2027 Earnings - Defense World
Research Analysts Issue Forecasts for Clene Q1 Earnings - Defense World
What is HC Wainwright’s Estimate for Clene FY2028 Earnings? - Defense World
Clene stock touches 52-week low at $3.8 amid market challenges By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $31 target on Clene stock post-results By Investing.com - Investing.com Canada
Clene stock touches 52-week low at $3.8 amid market challenges - Investing.com
Clene to Participate in Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025 - StreetInsider.com
H.C. Wainwright maintains $31 target on Clene stock post-results - Investing.com
Clene (NASDAQ:CLNN) Given “Buy” Rating at HC Wainwright - Defense World
Clene to Present at Jones Las Vegas Technology and Innovation Conference - citybuzz -
Clene’s (CLNN) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Clene Inc. Reports 2024 Financial Results and Strategic Plans - TipRanks
Clene Inc (CLNN) Reports Q4 EPS of -$5.67, Revenue of $0.36M, Missing Analyst Estimates - GuruFocus.com
Clene Inc. Files For Mixed Shelf Of Up To $160 MillionSEC Filing -March 24, 2025 at 04:51 pm EDT - Marketscreener.com
Clene (NASDAQ: CLNN) Plans 2025 NDA Submission Following Positive ALS Trial Data - The Globe and Mail
Clene Inc. reports results for the quarter ended December 31Earnings Summary - TradingView
Clene Inc. (CLNN) Reports Q4 Loss, Lags Revenue Estimates - MSN
Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights - The Manila Times
Breakthrough: Clene's ALS Treatment Shows 11.9-Month Survival Benefit in Severe Cases - StockTitan
BiomednewsbreaksClene Inc. (NASDAQ: CLNN) Unveils Progress On CNM-Au8(R), Eyes Potential Fast-Track FDA Approval - MENAFN.COM
Bullish Clene Insiders Loaded Up On US$583.4k Of Stock - Yahoo Finance
Clene Inc. shareholder general resonance sells $12,091 in stock By Investing.com - Investing.com Australia
Clene Inc. shareholder general resonance sells $12,091 in stock - Investing.com
Dually-Listed Aerospace Stock Finds Premarket Success Following Key Announcement - The Globe and Mail
D. Boral Capital Reaffirms Buy Rating for Clene (NASDAQ:CLNN) - Defense World
HC Wainwright Reaffirms “Buy” Rating for Clene (NASDAQ:CLNN) - Defense World
H.C. Wainwright maintains Clene stock Buy rating, $31 target - Investing.com India
H.C. Wainwright maintains Clene stock Buy rating, $31 target By Investing.com - Investing.com South Africa
Clene reports ALS treatment survival benefit in trial By Investing.com - Investing.com Australia
Utah Biotech's Treatment Demonstrates Significant Survival Advantage for ALS Patients - Streetwise Reports
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Reports CNM-Au8 Significantly Improves Survival in ALS Patients - Financial Content
Clene Inc. (NASDAQ: CLNN) to Present CNM-Au8(R) Updates at 37th Annual Roth Conference - Financial Content
Clene reports ALS treatment survival benefit in trial - Investing.com India
Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment - The Manila Times
Breakthrough: New ALS Drug Extends Patient Survival by 198 Days in Major Clinical Study - StockTitan
Clene (NASDAQ: CLNN) to Highlight Latest Achievements, Next Steps for CNM-Au8(R), at Q1 Virtual Investor Summit - Barchart
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Participate in 37th Annual Roth Conference - Financial Content
Clene to Present at the 37TH Annual Roth Conference - The Manila Times
Clene Inc. to Participate in 37th Annual Roth Conference with Virtual Fireside Chat and Investor Meetings - Nasdaq
Can Clene's Neurodegenerative Disease Treatments Transform ALS and MS Care? - StockTitan
Investornewsbreaks Clene Inc. (NASDAQ: CLNN) To Participate In 37Th Annual Roth Conference - MENAFN.COM
Clene (CLNN) to Release Quarterly Earnings on Wednesday - Defense World
Silicon Valley - Financial Content
Clene (NASDAQ: CLNN) CEO and CFO to Present at Investor Summit Virtual on March 11 - The Globe and Mail
New analyses in ALS planned to aid CNM-Au8’s accelerated approval - ALS News Today
What Will Clene Executives Reveal at the Upcoming Investor Summit? - StockTitan
Clene (NASDAQ:CLNN) Earns “Buy” Rating from HC Wainwright - Defense World
Clene (NASDAQ:CLNN) Earns Buy Rating from D. Boral Capital - Defense World
Clene Inc (CLNN) 財務データ
収益
当期純利益
現金流量
EPS
Clene Inc (CLNN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| General Resonance LLC | 10% Owner |
Mar 18 '25 |
Sale |
4.45 |
1,333 |
5,932 |
712,252 |
| MATLIN DAVID J | Director |
Sep 30 '24 |
Buy |
4.75 |
92,307 |
438,458 |
444,491 |
| Mortenson Mark | Chief Science Officer |
Sep 30 '24 |
Buy |
4.75 |
20,512 |
97,432 |
28,949 |
| Etherington Robert Dee | Chief Executive Officer |
Sep 30 '24 |
Buy |
4.75 |
10,000 |
47,500 |
40,149 |
| Etherington Robert Dee | Chief Executive Officer |
Jul 29 '24 |
Option Exercise |
3.00 |
27,320 |
81,960 |
30,149 |
| General Resonance LLC | 10% Owner |
Apr 30 '24 |
Sale |
0.42 |
13,000 |
5,416 |
15,326,712 |
| General Resonance LLC | 10% Owner |
May 01 '24 |
Sale |
0.40 |
13,000 |
5,148 |
15,313,712 |
| General Resonance LLC | 10% Owner |
Apr 24 '24 |
Sale |
0.33 |
10,000 |
3,278 |
15,349,712 |
| General Resonance LLC | 10% Owner |
Apr 09 '24 |
Sale |
0.39 |
22,500 |
8,674 |
15,428,212 |
0.27%
0.35%
大文字化:
|
ボリューム (24 時間):